Cape Investment Advisory’s Ascendis Pharma A/S ASND Stock Holding History

Cape Investment Advisory’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.33K	Buy	+20	New	+$4.67K	﹤0.01%	1013
2026 Q1	–	Sell	-5	Closed	-$1.07K	–	290
2025 Q4	$1.07K	Buy	+5	New	+$1.03K	﹤0.01%	1184

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Cape Investment Advisory's ASND Position: Q2 2026 in Review

Cape Investment Advisory opened a new position in Ascendis Pharma A/S (ASND) in Q2 2026: 20 shares worth $5.33K. The stake represents ﹤0.01% of the portfolio and ranks #1013 among its holdings. This is a return to the name: Cape Investment Advisory previously reported a position in ASND as recently as Q4 2025.

Cape Investment Advisory first reported a position in ASND in Q4 2025 and has held it in 2 quarters since. 313 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Cape Investment Advisory held 20 shares of Ascendis Pharma A/S worth $5.33K as of Q2 2026.
Ascendis Pharma A/S was a new Cape Investment Advisory position in Q2 2026.
Ascendis Pharma A/S made up ﹤0.01% of Cape Investment Advisory's portfolio in Q2 2026, its #1013 holding.
Cape Investment Advisory first reported a position in Ascendis Pharma A/S in Q4 2025 and has held it in 2 quarters since.
313 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Cape Investment Advisory's 13F filing for Q2 2026, filed 23 Jul 2026.